(TheNewswire)
-
MindBio Co-Founder Justin Hanka andscientific collaborators to present Phase 1 Microdosing LSD ClinicalTrial data in Miami on November 4 th 2022
Vancouver, British Columbia – TheNewswire - Sept 15, 2022 –Blackhawk Growth Corp. (CSE:BLR ) ; ( Frankfurt:0JJ)(the “ Company ” or “ Blackhawk ”) is pleased to announce that itswholly-owned subsidiary, MindBio Therapeutics (“MindBio”), will bepresenting its Phase 1 clinical trial data from its LSD (Lysergic AcidDiethylamide) Microdosing studies in Miami on November 4 th 2022 at the WonderlandConvention , the world’s largestpsychedelics event.
MindBio is a clinical stage drug development companycreating a safe and effective microdosing treatment protocol usingpsychedelic medicines to treat mental health conditions. MindBio’sclinical trials have the unique advantage of having regulatoryapprovals for clinical trial participants to take their microdoses ofLSD out in the community and at home in the same way they would takeany other medicine. MindBio remains the only organisation in theworld to have clinical trials running with this kind of regulatoryapproval for clinical trial participants to take LSD in microdosesoutside of the laboratory.
Microdosing involves taking repeated small doses of apsychedelic medicine (in this case LSD), where a microdose issubperceptual and the drug’s effects are non-hallucinogenic.
The Phase 1 clinicaltrials involved a randomized doublemasked and placebo-controlled administration of LSD or placebo in 80healthy participants.
MindBio wants to be first to market with a microdosingregimen and predictive treatment protocol for microdosing psychedelicmedicines with the potential to:
-
have potential lower side effect risk profile toexisting pharmacological treatments such as anti-depressants andbenzodiazapines for the treatment of a range of mental healthconditions;
-
offer less risk of harm and disruption to dailyactivity than large, one off doses of psychedelics;
-
affect brain neuroplasticity after acuteadministration, in the same way that larger hallucinogenic dosesaffect the brain, yet the patient is still able to get on with theirnormal day after ingesting the microdose. This is not possible witha psychedelic macro-dosing treatment session which requires an inclinic therapeutic session guided by clinicians over manyhours.
-
is a scalable solution to global mental healthtreatment.
The results of this important clinical trial will formthe basis for advancing two separate Phase 2 clinical trials inpatients with Major Depressive Disorder and in patients with latestage cancer suffering emotional distress. Both Phase 2 clinicaltrials are currently in development.
“We are very pleased to have completed Phase 1clinical trials and are looking forward to progressing ourcommercialization agenda” said Frederick Pels, CEO of Blackhawk.
MindBio is planning to spin out of Blackhawk and liston the Canadian Securities Exchange and preparations are progressingafter some delay. MindBio is hoping to make further announcements onthe timing on the spin out shortly.
About Blackhawk Growth
Blackhawk is an investment holding company looking tocreate substantial value for its shareholders through the acquisitionand development of high growth companies. It has focused itsinvestments in the health, cannabis and cannabidiol industries in bothCanada and the United States. Its portfolio of companies includes SacPharma, Spaced Food, Stable Foods, Digital Mind Therapeutics, BlumDistributors Ltd. and MindBio Therapeutics.
The Company diligently posts updates through videosfrom the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk groupsupporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com .
For further information please contact:
Frederick Pels, Chief ExecutiveOfficer
(403)-991-7737
fred@ blackhawkgrowth.com
Cautionary NoteRegarding Forward-Looking Statement
All statements in this pressrelease, other than statements of historical fact, are “forward-looking information”with respect to the Company within the meaning of applicablesecurities laws, including with respect to transaction and futureoperations of MindBio Therapeutics Pty Ltd. The Company providesforward-looking statements for the purpose of conveying informationabout current expectations and plans relating to the future andreaders are cautioned that such statements may not be appropriate forother purposes. By its nature, this information is subject to inherentrisks and uncertainties that may be general or specific and which giverise to the possibility that expectations, forecasts, predictions,projections or conclusions will not prove to be accurate, thatassumptions may not be correct and that objectives, strategic goalsand priorities will not be achieved. These risks and uncertaintiesinclude but are not limited those identified and reported in theCompany’s public filings under the Company’s SEDAR profile atwww.sedar.com. Although the Company has attempted to identifyimportant factors that could cause actual actions, events or resultsto differ materially from those described in forward-lookinginformation, there may be other factors that cause actions, events orresults not to be as anticipated, estimated or intended. There can beno assurance that such information will prove to be accurate as actualresults and future events could differ materially from thoseanticipated in such statements. The Company disclaims any intention orobligation to update or revise any forward-looking information,whether as a result of new information, future events or otherwiseunless required by law.
Copyright (c) 2022 TheNewswire - All rights reserved.